HomeBUSINESS
BUSINESS

Perjeta Gets Japan OK as Neoadjuvant, Adjuvant Therapy for HER2 Breast Cancer
(Oct.11.2018)

Chugai Pharmaceutical said on October 10 that it has received approval for its cancer agent Perjeta (pertuzumab) for an additional indication of neoadjuvant and adjuvant therapy for HER2-positive early breast cancer ...
(LOG IN FOR FULL STORY)